BiondVax Pharmaceuticals Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was ILS 9.42 million compared to ILS 8.19 million a year ago. Basic loss per share from continuing operations was ILS 8 compared to ILS 8 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4576 USD | +1.69% | -2.64% | -23.14% |
1st Jan change | Capi. | |
---|---|---|
-23.14% | 1.96M | |
+33.22% | 50.85B | |
+0.70% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+10.75% | 26.11B | |
-21.63% | 19.13B | |
+8.97% | 13.05B | |
+27.42% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- SCNI Stock
- News Scinai Immunotherapeutics Ltd.
- BiondVax Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022